Reasons to Expect Strong Bristol-Myers Earnings


Recent market volatility and global pressures have tempered investors' expectations for a strong earnings season, but not all companies will do poorly. Although Bristol-Myers Squibb shares -- down some 7% year to date -- is not off to a good start in 2016, the multinational drug giant belongs on any short list of companies poised to beat Wall Street's earnings estimates.



from Biotech News